Applicant citizenship:
Host country: United States
Years since PhD: Applicants must have a MD and/or PhD (or equivalent) and demonstrate exceptional promise.
Award: $900 000
Award Duration (years): 3
Research costs:
Benefits:
Mobility rule: No
Subjects: Life Sciences , Medicine and Health Sciences
Additional comments: In 2017, HDI will award five grants of up to $900,000 each over three years through the program. Grant recipients also will receive committed drug development and project management support through HDI's Innovation Support Center. Areas of interest include treatment strategies that are not gene specific but might be broadly applicable across many patients; therapies that may be effective in later stages of disease; the development of gene-delivery vectors or gene-modifying strategies that can be used as a general platform to target specific retinal cell types, deliver/correct genes with large coding regions, specifically target outer retinal cells, and impact cells across the entire retinal area; therapies that address juvenile macular degeneration; regenerative medicine therapies that focus on stem cells differentiated into photoreceptor cells; and novel targets to address unmet need. Of particular interest is the targeting of pathways and processes that might affect retinal dystrophies and vision, with the ultimate goal of advancing translation of research into drugs and cell-based therapies. In most cases, device development is not supported.
How to apply? For further eligibility requirements and the application process, please visit: Official Funding website
This entry has been last updated: 2020-05-24 11:53:16